Ultragenyx Pharmaceutical Inc.
http://www.ultragenyx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ultragenyx Pharmaceutical Inc.
Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone
Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.
Bespoke Gene Therapy ‘Playbook’ Outlines Platform Approach To AAV-Based Treatments
Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.
EMA Grants First Two PRIME Designations In 2024 To Ultragenyx & Sangamo
Ultragenyx’s antisense oligonucleotide for treating Angelman syndrome and Sangamo’s gene therapy for Fabry disease are the latest products to make it onto the European Medicines Agency’s priority medicines scheme.
From Whiskey To Cancer Drugs: George Nakayama’s Unusual Journey
From extricating Daiichi Sankyo from the Ranbaxy acquisition to enabling the rapid development of blockbuster Enhertu, George Nakayama has had a winding career path through multiple key strategic positions and decisions. He shares his experience and insights, and a good dose of humor, in this exclusive interview.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Dimension Therapeutics
- GeneTx Biotherapeutics LLC
- Ultragenyx
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice